Concepedia

Giridhar Tirucherai

GT

26

Publications

1.7K

Citations

20

H-Index

1999

Active since

Affiliations

Bristol-Myers Squibb (United States)(Current)

University of Missouri–Kansas City

University of California San Diego

Bristol-Myers Squibb (Sweden)

Texas Liver Institute

Giridhar Tirucherai is an author at Bristol-Myers Squibb (United States) specializing in pharmacology, medicine, and pharmacotherapy.

Top concepts

Publications per year

1999–2025

26

Publications

26

Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end‐stage renal disease on hemodialysis

Xiaoli Wang, Giridhar Tirucherai, Thomas Marbury et al. · The Journal of Clinical Pharmacology · 2015 · 280 citations · Full text

, , +19

Pegbelfermin (BMS‐986036), PEGylated FGF21, in Patients with Obesity and Type 2 Diabetes: Results from a Randomized Phase 2 Study

Edgar D. Charles, Brent A. Neuschwander‐Tetri, Juan P. Frías et al. · Obesity · 2018 · 243 citations · Full text

Effect of Activated Charcoal on Apixaban Pharmacokinetics in Healthy Subjects

Xiaoli Wang, Sabiha Mondal, Jessie Wang et al. · American Journal of Cardiovascular Drugs · 2013 · 153 citations · Full text

Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial

Adam L. Boxer, Irfan Qureshi, Michael K. Ahlijanian et al. · The Lancet Neurology · 2019 · 137 citations

, , +3

BMS‐986263 in patients with advanced hepatic fibrosis: 36‐week results from a randomized, placebo‐controlled phase 2 trial

Eric Lawitz, Diane E. Shevell, Giridhar Tirucherai et al. · Hepatology · 2021 · 89 citations · Full text

Rows per page

1–5 of 26